What Is a Liquid Biopsy and How Does It Detect Cancer?

A Blood Test That Can Spot Cancer

For decades, confirming a cancer diagnosis meant cutting into a patient's body to extract a piece of suspicious tissue. That approach — the traditional tissue biopsy — remains the gold standard in many situations. But a quieter revolution has been gathering pace in oncology labs: a simple blood draw that can detect cancer by hunting for tiny molecular fingerprints the tumor leaves in your bloodstream. Scientists call it a liquid biopsy.

The concept sounds almost too good to be true. But driven by advances in DNA sequencing, liquid biopsies are moving from research tools into routine clinical practice — and potentially reshaping how cancer is caught, monitored, and treated.

What Exactly Is a Liquid Biopsy?

A liquid biopsy is a blood test that scans for biological material shed by tumors into the circulatory system. Unlike a traditional biopsy, which requires a surgeon to remove a piece of tissue from a tumor, a liquid biopsy requires only a vial of blood drawn from a patient's arm, according to the Cleveland Clinic.

The test looks for several types of tumor-derived material floating in the bloodstream:

• Circulating tumor DNA (ctDNA) — short fragments of DNA that cancer cells release as they die and break apart
• Circulating tumor cells (CTCs) — whole cancer cells that have detached from a tumor and entered the blood
• Exosomes — tiny vesicles secreted by tumor cells carrying proteins and genetic material
• Cell-free RNA and proteins — additional molecular signals associated with cancer activity

Of these, ctDNA has attracted the most clinical interest because it can be detected with high-sensitivity DNA sequencing even when tumors are small and early-stage.

How Does the Test Work?

Once blood is drawn, laboratory technicians isolate cell-free DNA (cfDNA) — all the DNA fragments floating freely in the plasma, not locked inside cells. The challenge is that most cfDNA comes from normal healthy cells; cancer-derived ctDNA may represent as little as 0.1% of the total, especially in early-stage disease.

This is where next-generation sequencing (NGS) becomes essential. Sophisticated sequencing machines read millions of DNA fragments at once, and algorithms compare those sequences against a reference genome, hunting for the telltale mutations that mark cancer DNA. According to a comprehensive review in Nature's Signal Transduction and Targeted Therapy, advances in error-correction sequencing techniques have dramatically improved sensitivity, allowing labs to detect ctDNA carrying tumor-specific mutations even at vanishingly low concentrations.

Some newer multi-cancer tests go further, combining ctDNA analysis with patterns of DNA methylation — chemical tags that control gene activity and differ markedly between cancer and normal cells — to identify not just whether cancer is present, but where in the body it likely originated.

What Can Liquid Biopsies Be Used For?

Liquid biopsies currently serve several distinct clinical purposes, as outlined by the Association of American Medical Colleges (AAMC):

• Treatment selection: In patients already diagnosed with advanced cancer, ctDNA can identify the specific mutations driving tumor growth, helping oncologists choose targeted therapies. Several companion diagnostic tests are FDA-approved for this purpose across breast, lung, colorectal, prostate, and ovarian cancers.
• Monitoring treatment response: Falling ctDNA levels in the blood can signal that a treatment is working; rising levels may indicate resistance or recurrence — often weeks or months before it would show up on a scan.
• Detecting minimal residual disease: After surgery or chemotherapy, liquid biopsies can search for traces of remaining cancer cells that imaging cannot see.
• Early screening: The most ambitious application — catching cancer before symptoms appear. In 2024, the U.S. FDA approved Shield, the first liquid biopsy test for colorectal cancer screening in average-risk adults.

Multi-Cancer Early Detection: The Big Promise

The frontier that has generated the most excitement — and the most debate — is multi-cancer early detection (MCED): a single blood test that screens for dozens of cancer types simultaneously. Tests like GRAIL's Galleri and Exact Sciences' CancerGuard are already commercially available in the United States as laboratory-developed tests, even though they await full FDA approval for screening.

A 2023 study published on PubMed Central found that MCED tests showed strong promise for detecting cancers that currently lack standard screening programs — including pancreatic, ovarian, and liver cancers, which are often diagnosed only at late, hard-to-treat stages.

Critics note important caveats: false positives can cause anxiety and lead to unnecessary procedures; sensitivity for very early-stage tumors remains limited; and rigorous large-scale randomized trials proving that MCED tests actually reduce cancer mortality are still underway.

Why It Matters

Traditional tissue biopsies are invasive, expensive, and can only sample one location in a tumor at a time — missing the genetic diversity that often exists across a large tumor or between primary and metastatic sites. Liquid biopsies offer a real-time, comprehensive snapshot of tumor genetics from a simple blood draw, which can be repeated as often as needed.

If multi-cancer screening tests eventually prove effective in large populations, they could fundamentally shift oncology from a disease-treatment model toward a disease-prevention model — catching cancers when they are still small, localized, and most curable. That shift would represent one of the most significant advances in cancer medicine in a generation.